Gossamer Bio Financials
This page shows Gossamer Bio (GOSS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Gossamer Bio remains a development-stage business whose economics are dominated by research spending, making revenue swings decisive for cash burn.
FY2024's near-cash break-even did not mark a durable turn, because revenue dropped to$48.5M in FY2025 just as R&D rose to$174.1M . With operating cash flow swinging from-$3.5M to-$171.3M , the model still behaves like a research platform funded by intermittent inflows rather than a self-funding operating business.
Liquidity and solvency are telling different stories: FY2025 current assets of
The cost base is overwhelmingly research-led, with FY2025 R&D at
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Gossamer Bio's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Gossamer Bio has an operating margin of -352.2%, meaning the company retains $-352 of operating profit per $100 of revenue. This below-average margin results in a low score of 17/100, suggesting thin profitability after operating expenses. This is down from -52.2% the prior year.
Gossamer Bio's revenue declined 57.7% year-over-year, from $114.7M to $48.5M. This contraction results in a growth score of 1/100.
With a current ratio of 2.64, Gossamer Bio holds $2.64 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 71/100.
While Gossamer Bio generated -$171.3M in operating cash flow, capex of $79K consumed most of it, leaving -$171.3M in free cash flow. This results in a low score of 4/100, reflecting heavy capital investment rather than weak cash generation.
Gossamer Bio scores -13.82, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($66.5M) relative to total liabilities ($295.0M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Gossamer Bio passes 0 of 7 computable financial strength tests (2 of the nine could not be computed from available data). No profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
For every $1 of reported earnings, Gossamer Bio generates $1.01 in operating cash flow (-$171.3M OCF vs -$170.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Gossamer Bio earns $-15.5 in operating income for every $1 of interest expense (-$170.7M vs $11.0M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Gossamer Bio generated $48.5M in revenue in fiscal year 2025. This represents a decrease of 57.7% from the prior year.
Gossamer Bio's EBITDA was -$170.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 188.9% from the prior year.
Gossamer Bio reported -$170.4M in net income in fiscal year 2025. This represents a decrease of 201.4% from the prior year.
Gossamer Bio earned $-0.75 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 200.0% from the prior year.
Cash & Balance Sheet
Gossamer Bio generated -$171.3M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 4840.7% from the prior year.
Gossamer Bio held $37.7M in cash against $0 in long-term debt as of fiscal year 2025.
Gossamer Bio had 234M shares outstanding in fiscal year 2025. This represents an increase of 3.1% from the prior year.
Margins & Returns
Gossamer Bio's operating margin was -352.2% in fiscal year 2025, reflecting core business profitability. This is down 300.0 percentage points from the prior year.
Gossamer Bio's net profit margin was -351.5% in fiscal year 2025, showing the share of revenue converted to profit. This is down 302.2 percentage points from the prior year.
Capital Allocation
Gossamer Bio invested $174.1M in research and development in fiscal year 2025. This represents an increase of 25.7% from the prior year.
Gossamer Bio invested $79K in capex in fiscal year 2025, funding long-term assets and infrastructure.
GOSS Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $17.0M+22.9% | $13.8M+3.8% | $13.3M+15.7% | $11.5M+16.2% | $9.9M | N/A | $9.5M-90.1% | $95.8M |
| Cost of Revenue | $42.4M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | -$25.4M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $43.1M-12.0% | $48.9M+7.5% | $45.5M+9.5% | $41.6M+9.3% | $38.0M | N/A | $34.9M-0.5% | $35.1M |
| SG&A Expenses | $18.7M+71.9% | $10.9M+16.1% | $9.4M+8.2% | $8.7M+0.2% | $8.7M | N/A | $8.5M-1.9% | $8.7M |
| Operating Income | -$44.9M+2.5% | -$46.0M+6.3% | -$49.1M-26.7% | -$38.8M-5.3% | -$36.8M | N/A | -$33.9M-165.1% | $52.1M |
| Interest Expense | $2.8M+0.1% | $2.8M+0.1% | $2.7M+0.1% | $2.7M-0.1% | $2.7M | N/A | $2.7M-6.2% | $2.9M |
| Income Tax | N/A | N/A | $0 | $0 | N/A | N/A | -$1.1M-125.5% | $4.4M |
| Net Income | -$46.7M+1.2% | -$47.2M+2.0% | -$48.2M-26.0% | -$38.3M-4.5% | -$36.6M | N/A | -$30.8M-162.6% | $49.2M |
| EPS (Diluted) | $-0.20 | N/A | $-0.21-23.5% | $-0.17-6.3% | $-0.16 | N/A | $-0.14-163.6% | $0.22 |
GOSS Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $128.9M-25.2% | $172.2M-17.5% | $208.8M-13.3% | $240.9M-14.1% | $280.6M-11.0% | $315.3M-10.1% | $350.9M-6.0% | $373.4M |
| Current Assets | $124.5M-25.7% | $167.6M-17.8% | $204.0M-13.5% | $235.9M-14.4% | $275.5M-11.1% | $309.9M-10.0% | $344.3M-7.2% | $370.9M |
| Cash & Equivalents | $41.0M+8.7% | $37.7M+322.4% | $8.9M-66.0% | $26.3M-9.3% | $29.0M-37.0% | $46.1M+61.9% | $28.5M-67.2% | $86.9M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $9.3M-24.3% | $12.2M+32.3% | $9.2M+22.0% | $7.6M+15.1% | $6.6M+23.3% | $5.3M-19.0% | $6.6M+81.5% | $3.6M |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $290.4M-1.6% | $295.0M+1.3% | $291.2M+1.4% | $287.0M+0.1% | $286.8M+0.4% | $285.8M-3.7% | $296.7M+1.7% | $291.9M |
| Current Liabilities | $56.5M-10.9% | $63.4M+2.1% | $62.1M+15.9% | $53.6M+11.1% | $48.2M+7.1% | $45.0M-11.9% | $51.1M+13.1% | $45.2M |
| Long-Term Debt | $198.8M | N/A | N/A | N/A | N/A | $0 | $0 | $0 |
| Total Equity | -$161.5M-31.5% | -$122.8M-49.1% | -$82.3M-78.6% | -$46.1M-637.7% | -$6.3M-121.2% | $29.5M-45.5% | $54.1M-33.6% | $81.5M |
| Retained Earnings | -$1.5B-3.2% | -$1.4B-3.4% | -$1.4B-3.6% | -$1.3B-2.9% | -$1.3B-2.9% | -$1.3B-2.7% | -$1.2B-2.6% | -$1.2B |
GOSS Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$38.7M+19.9% | -$48.3M-33.6% | -$36.2M+23.1% | -$47.1M-18.5% | -$39.7M-12.0% | -$35.5M-10.8% | -$32.0M-127.5% | $116.3M |
| Capital Expenditures | $0 | $0 | $0-100.0% | $53K+103.8% | $26K | $0 | $0 | $0 |
| Free Cash Flow | -$38.7M+19.9% | -$48.3M-33.6% | -$36.2M+23.2% | -$47.1M-18.5% | -$39.8M-12.0% | -$35.5M-10.8% | -$32.0M-127.5% | $116.3M |
| Investing Cash Flow | $41.6M-43.1% | $73.2M+330.0% | $17.0M-61.4% | $44.1M+100.0% | $22.1M-58.5% | $53.2M+298.9% | -$26.8M+54.7% | -$59.1M |
| Financing Cash Flow | $512K-87.1% | $4.0M+111.3% | $1.9M+1891.5% | $94K-81.3% | $504K | $0-100.0% | $281K+103.0% | -$9.2M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
GOSS Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | -149.8% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -264.6%+69.0pp | -333.6%+35.8pp | -369.4%-32.0pp | -337.4%+34.8pp | -372.2% | N/A | -357.8%-412.2pp | 54.4% |
| Net Margin | -275.2%+67.1pp | -342.3%+20.4pp | -362.7%-29.6pp | -333.1%+37.4pp | -370.5% | N/A | -324.9%-376.3pp | 51.4% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | -56.9%-117.3pp | 60.4% |
| Return on Assets | -36.2%-8.8pp | -27.4%-4.3pp | -23.1%-7.2pp | -15.9%-2.8pp | -13.1% | N/A | -8.8%-22.0pp | 13.2% |
| Current Ratio | 2.20-0.4 | 2.64-0.6 | 3.28-1.1 | 4.40-1.3 | 5.71-1.2 | 6.88+0.1 | 6.74-1.5 | 8.21 |
| Debt-to-Equity | N/A | N/A | N/A | N/A | N/A | 0.000.0 | 0.000.0 | 0.00 |
| FCF Margin | -228.4%+121.8pp | -350.1%-78.1pp | -272.1%+138.0pp | -410.1%-8.1pp | -402.0% | N/A | -337.9%-459.3pp | 121.4% |
Note: Shareholder equity is negative (-$122.8M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Frequently Asked Questions
What is Gossamer Bio's annual revenue?
Gossamer Bio (GOSS) reported $48.5M in total revenue for fiscal year 2025. This represents a -57.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Gossamer Bio's revenue growing?
Gossamer Bio (GOSS) revenue declined by 57.7% year-over-year, from $114.7M to $48.5M in fiscal year 2025.
Is Gossamer Bio profitable?
No, Gossamer Bio (GOSS) reported a net income of -$170.4M in fiscal year 2025, with a net profit margin of -351.5%.
What is Gossamer Bio's EBITDA?
Gossamer Bio (GOSS) had EBITDA of -$170.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Gossamer Bio's operating margin?
Gossamer Bio (GOSS) had an operating margin of -352.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Gossamer Bio's net profit margin?
Gossamer Bio (GOSS) had a net profit margin of -351.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Gossamer Bio's free cash flow?
Gossamer Bio (GOSS) generated -$171.3M in free cash flow during fiscal year 2025. This represents a -4840.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Gossamer Bio's operating cash flow?
Gossamer Bio (GOSS) generated -$171.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Gossamer Bio's total assets?
Gossamer Bio (GOSS) had $172.2M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Gossamer Bio's capital expenditures?
Gossamer Bio (GOSS) invested $79K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Gossamer Bio spend on research and development?
Gossamer Bio (GOSS) invested $174.1M in research and development during fiscal year 2025.
What is Gossamer Bio's current ratio?
Gossamer Bio (GOSS) had a current ratio of 2.64 as of fiscal year 2025, which is generally considered healthy.
What is Gossamer Bio's return on assets (ROA)?
Gossamer Bio (GOSS) had a return on assets of -98.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Gossamer Bio's cash runway?
Based on fiscal year 2025 data, Gossamer Bio (GOSS) had $37.7M in cash against an annual operating cash burn of $171.3M. This gives an estimated cash runway of approximately 3 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Gossamer Bio's debt-to-equity ratio negative or not reported?
Gossamer Bio (GOSS) has negative shareholder equity of -$122.8M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Gossamer Bio's Altman Z-Score?
Gossamer Bio (GOSS) has an Altman Z-Score of -13.82, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Gossamer Bio's Piotroski F-Score?
Gossamer Bio (GOSS) has a Piotroski F-Score of 0 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Gossamer Bio's earnings high quality?
Gossamer Bio (GOSS) has an earnings quality ratio of 1.01x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Gossamer Bio cover its interest payments?
Gossamer Bio (GOSS) has an interest coverage ratio of -15.5x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Gossamer Bio?
Gossamer Bio (GOSS) scores 33 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.